A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer

Shin, Vivian Y.; Ng, Enders K.W.; Chan, Vivian; Kwong, Ava; Chu, Kent‐Man

doi:10.1186/s12943-015-0473-3

Cited by 93 publications

(69 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, miR‐627‐5p, which is regulated by small nucleolar RNA host gene 15 (SNHG15), represses the expressions of cyclin dependent kinase 6 (CDK6) and SRY‐box transcription factor 2 (SOX‐2) to suppress the tumorigenesis of GBM . However, the level of miR‐627 is markedly higher in gastric cancer patients compared to healthy controls, indicating an oncogenic role of miR‐627 in gastric cancer . But, the function of miR‐627‐5p has not been investigated in HCC.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‐627‐5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator

Wang

Chen

Wang

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignant tumour. An increasing number of studies indicate that microRNAs (miRNAs) are critical regulators in the carcinogenesis and progression of HCC. MiR-627-5p has been identified as a tumour suppressor in colorectal cancer and glioblastoma multiforme. However, the function of miR-627-5p in HCC progression remains unclear yet. In our present study, miR-627-5p was determined to be low-expressed in HCC tissues and cell lines. Furthermore, miR-627-5p was expressed at significantly lower levels in HCC tissues with tumour size >5 cm or advanced tumour stages (III+IV). Additionally, HCC patients with low miR-627-5p level had a significantly poorer overall survival. Functionally, ectopic expression of miR-627-5p obviously inhibited the proliferation, and induced G1 phase arrest and apoptosis of Hep3B and SMMC-7721 cells. Conversely, miR-627-5p silencing facilitated HCC cell proliferation, cell cycle progression and apoptosis resistance. In vivo experiments further confirmed that miR-627-5p overexpression repressed the growth of Hep3B cells in mice. Mechanistically, BCL3 transcription coactivator was predicted as a direct target of miR-627-5p. MiR-627-5p overexpression reduced, whereas miR-627-5p knockdown enhanced the expression of BCL3 protein in HCC cells. Luciferase reporter assay confirmed the direct binding between miR-627-5p and 3′UTR of BCL3.The expression of BCL3 protein was negatively correlated with miR-627-5p level in HCC tissues. More importantly, re-expression of BCL3 partially reversed miR-627-5p induced inhibitory effects on Hep3B cells. In conclusion, these results demonstrated that miR-627-5p functioned as a tumour suppressor in HCC possibly by attenuating BCL3. This finding might offer a new therapeutic target for HCC treatment. K E Y W O R D SBCL3, hepatocellular carcinoma, miR-627-5p, proliferation, tumour growth

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA‐627‐5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator

Wang

Chen

Wang

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…In a study carried out by a group of researchers to analyze miRNA expression profiles across multiple cancers using data sets obtained from The Cancer Genome Atlas (TCGA), miR-629 was found to be upregulated in various cancers, such as bladder, head and neck, lung, kidney, breast and uterine cancer 14. It was also reported that circulating miR-629 is upregulated in lung cancer patients and can potentially be used in diagnosis of lung and gastric cancer 15,16…”

Section: Introductionmentioning

confidence: 99%

Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1′S-1′-acetoxychavicol acetate via regulating RSU1

Phuah¹,

Azmi²,

Awang³

et al. 2017

OTT

View full text Add to dashboard Cite

“…Recent studies have reported that miR-199a-3p plays an important role in suppressing cell proliferation and migration in various tumors, such as prostate cancer [27], colorectal cancer [28], breast cancer [29], glioma [30], osteosarcoma [31] and pancreatic ductal adenocarcinoma [32]. Further studies have demonstrated that miR-199a-3p is a prognosis and diagnosis biomarker in hepatocellular carcinoma [33], gastric cancer [34] and colorectal cancer [35]. In addition, Fornari et al .…”

Section: Discussionmentioning

confidence: 99%

MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1

Xia

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Several studies have reported reduced miRNA-199a-3p (miR-199a-3p) in different human malignancies, however, little is known about miR-199a-3p in cholangiocarcinoma cells. In this study, we demonstrate the essential role and mechanism of miR-199a-3p in regulating cisplatin sensitivity in cholangiocarcinoma cell lines. Using a CCK-8 cell counting assay we found that expression of miR-199a-3p was positively correlated with cisplatin sensitivity in cholangiocarcinoma cell lines. MiR-199a-3p overexpression could decrease the proliferation rate and increase apoptosis of cholangiocarcinoma cells in the presence of cisplatin, while miR-199a-3p inhibition had the opposite effect. Further study demonstrated that mTOR was the target gene of miR-199a-3p, and that miR-199a-3p mimics could inhibit expression of mTOR, which consequently reduced the phosphorylation of its downstream proteins 4EBP1 and p70s6k. Rescue experiments proved that miR-199a-3p could increase the cisplatin sensitivity of cholangiocarcinoma cell lines by regulating mTOR expression. Moreover, we also found that miR-199a-3p overexpression could reduce cisplatin induced MDR1 expression by decreasing the synthesis and increasing the degradation of MDR1, thus enhancing the effectiveness of cisplatin in cholangiocarcinoma. In conclusion, miR-199a-3p could increase cisplatin sensitivity of cholangiocarcinoma cell lines by inhibiting the activity of the mTOR signaling pathway and decreasing the expression of MDR1.

show abstract

A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer

Cited by 93 publications

References 23 publications

MicroRNA‐627‐5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator

MicroRNA‐627‐5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator

Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1′S-1′-acetoxychavicol acetate via regulating RSU1

MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1

Contact Info

Product

Resources

About

A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer

Cited by 93 publications

References 23 publications

MicroRNA‐627‐5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator

MicroRNA‐627‐5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator

Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1&prime;S-1&prime;-acetoxychavicol acetate via regulating RSU1

MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1

Contact Info

Product

Resources

About

Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1′S-1′-acetoxychavicol acetate via regulating RSU1